ReP USP - Resultado da busca

Filtros : "Kang, Eun-Young" Limpar

Filtros

Indexado em
- indexado no current contents (2)
- indexado no embase (2)
- indexado no global health (2)
- indexado no medline (2)
- indexado no pubmed (2)

Collaboration
Normalized affiliation
Non normalized affiliation
- british columbia's ovarian cancer research (ovcare) program, bc cancer, vancouver general hospital, and university of british columbia, vancouver, bc (1)
- centre for cancer genetic epidemiology, department of oncology, university of cambridge, cambridge (1)
- centre for cancer research, the westmead institute for medical research, westmead (1)
- department of anatomical pathology, prince of wales hospital, sydney (1)
- department of gynecology and obstetrics, ribeirão preto medical school, university of são paulo, ribeirão preto (1)

Artigo de periodico
Increased FOXJ1 protein expression is associated with improved overall survival in high-grade serous ovarian carcinoma: an Ovarian Tumor Tissue Analysis Consortium Study (2023)
Weir, Ashley; Kang, Eun-Young; Meagher, Nicola S.; Nelson, Gregg S.; Ghatage, Prafull; Lee, Cheng-Han; Riggan, Marjorie J.; Ryan, Andy; Singh, Naveena; Alsop, Jennifer; Anglesio, Michael S.; Bisinoto, Christiani; Ramus, Susan J. ; Reis, Francisco José Candido dos
Source: British Journal of Cancer. Unidade: FMRP
Subjects: BIOMARCADORES, ADENOCARCINOMA, NEOPLASIAS OVARIANAS, PROGNÓSTICO, RNA MENSAGEIRO, ANÁLISE DE SOBREVIVÊNCIA
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
WEIR, Ashley et al. Increased FOXJ1 protein expression is associated with improved overall survival in high-grade serous ovarian carcinoma: an Ovarian Tumor Tissue Analysis Consortium Study. British Journal of Cancer, v. 128, n. 1, p. 137-147, 2023Tradução . . Disponível em: https://doi.org/10.1038/s41416-022-02014-y. Acesso em: 01 nov. 2024.
APA
Weir, A., Kang, E. -Y., Meagher, N. S., Nelson, G. S., Ghatage, P., Lee, C. -H., et al. (2023). Increased FOXJ1 protein expression is associated with improved overall survival in high-grade serous ovarian carcinoma: an Ovarian Tumor Tissue Analysis Consortium Study. British Journal of Cancer, 128( 1), 137-147. doi:10.1038/s41416-022-02014-y
NLM
Weir A, Kang E-Y, Meagher NS, Nelson GS, Ghatage P, Lee C-H, Riggan MJ, Ryan A, Singh N, Alsop J, Anglesio MS, Bisinoto C, Ramus SJ, Reis FJC dos. Increased FOXJ1 protein expression is associated with improved overall survival in high-grade serous ovarian carcinoma: an Ovarian Tumor Tissue Analysis Consortium Study [Internet]. British Journal of Cancer. 2023 ; 128( 1): 137-147.[citado 2024 nov. 01 ] Available from: https://doi.org/10.1038/s41416-022-02014-y
Vancouver
Weir A, Kang E-Y, Meagher NS, Nelson GS, Ghatage P, Lee C-H, Riggan MJ, Ryan A, Singh N, Alsop J, Anglesio MS, Bisinoto C, Ramus SJ, Reis FJC dos. Increased FOXJ1 protein expression is associated with improved overall survival in high-grade serous ovarian carcinoma: an Ovarian Tumor Tissue Analysis Consortium Study [Internet]. British Journal of Cancer. 2023 ; 128( 1): 137-147.[citado 2024 nov. 01 ] Available from: https://doi.org/10.1038/s41416-022-02014-y
Artigo de periodico
MCM3 is a novel proliferation marker associated with longer survival for patients with tubo-ovarian high-grade serous carcinoma (2022)
Kang, Eun-Young; Millstein, Joshua; Popovic, Gordana; Meagher, Nicola S.; Bolithon, Adelyn; Talhouk, Aline; Chiu, Derek S.; Anglesio, Michael S.; Leung, Betty; Tang, Katrina; Lambie, Neil; Pavanello, Marina; Ramus, Susan J.; Köbel, Martin; Reis, Francisco José Candido dos
Source: Virchows Archiv. Unidade: FMRP
Subjects: BIOMARCADORES, PROLIFERAÇÃO CELULAR, NEOPLASIAS OVARIANAS, RNA MENSAGEIRO, TAXA DE SOBREVIVÊNCIA
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
KANG, Eun-Young et al. MCM3 is a novel proliferation marker associated with longer survival for patients with tubo-ovarian high-grade serous carcinoma. Virchows Archiv, v. 480, n. 4, p. 855-871, 2022Tradução . . Disponível em: https://doi.org/10.1007/s00428-021-03232-0. Acesso em: 01 nov. 2024.
APA
Kang, E. -Y., Millstein, J., Popovic, G., Meagher, N. S., Bolithon, A., Talhouk, A., et al. (2022). MCM3 is a novel proliferation marker associated with longer survival for patients with tubo-ovarian high-grade serous carcinoma. Virchows Archiv, 480( 4), 855-871. doi:10.1007/s00428-021-03232-0
NLM
Kang E-Y, Millstein J, Popovic G, Meagher NS, Bolithon A, Talhouk A, Chiu DS, Anglesio MS, Leung B, Tang K, Lambie N, Pavanello M, Ramus SJ, Köbel M, Reis FJC dos. MCM3 is a novel proliferation marker associated with longer survival for patients with tubo-ovarian high-grade serous carcinoma [Internet]. Virchows Archiv. 2022 ; 480( 4): 855-871.[citado 2024 nov. 01 ] Available from: https://doi.org/10.1007/s00428-021-03232-0
Vancouver
Kang E-Y, Millstein J, Popovic G, Meagher NS, Bolithon A, Talhouk A, Chiu DS, Anglesio MS, Leung B, Tang K, Lambie N, Pavanello M, Ramus SJ, Köbel M, Reis FJC dos. MCM3 is a novel proliferation marker associated with longer survival for patients with tubo-ovarian high-grade serous carcinoma [Internet]. Virchows Archiv. 2022 ; 480( 4): 855-871.[citado 2024 nov. 01 ] Available from: https://doi.org/10.1007/s00428-021-03232-0

Digital Library of Intellectual Production of Universidade de São Paulo 2012 - 2024